CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer. - sprookjes - yvandenbroek - TriplyDB

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

http://www.wikidata.org/entity/Q35154029

about

3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding.

P2860

Q39186868-D81CE82C-8AB5-4000-A4A0-D48128CE8A8F Q47582263-1DFEDCC1-15C2-4F5D-8A0B-0A612C56442A

P2860

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

http://www.wikidata.org/entity/Q35154029

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@ast

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@en

type

label

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@ast

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@en

prefLabel

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@ast

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@en

P1433

Q35154029-E4754198-E985-4970-A35E-50EF5ECAE78B

P1476

Q35154029-5DD2CB66-07A2-436D-B9A6-35D6365DE9B8

P2093

Q35154029-26833899-73AE-48AF-B403-5ABAB94B1DAA

Q35154029-9CC78D15-06C2-4B98-92F3-EB5E9CB18606

Q35154029-A50138C4-BABF-4963-8A0C-CC7FFEBE9DB3

Q35154029-EF9CD0D7-89EA-49C6-AA66-0AFDDF9F89D9

P2860

Q35154029-0A867E26-3D7D-4A59-B97A-2D321292D0B5

Q35154029-0CE19237-C00E-4C28-85C5-004B8AF2CADC

Q35154029-30964299-E1FE-4DAF-943D-F7327BD35DE1

Q35154029-5C7B5952-D873-4646-BA78-5D94FB614373

Q35154029-69C1854B-AE67-4DE5-B02C-85B6C3A78A1D

Q35154029-91622D0A-C760-4B3C-B046-E23D0CDC3283

Q35154029-A21794B0-7C29-4878-8E65-75117EDE96AC

Q35154029-B8395BFA-BE07-4A34-8E1E-66BD604F6093

Q35154029-F9C3960A-E00F-4EEE-82C9-10D111765F44

P304

Q35154029-4119020B-F83D-4EA0-A70D-B62882376585

P31

Q35154029-C1EEF55F-596B-4AD7-8F90-B412643E2D55

P356

Q35154029-977563CA-9F1C-4B21-85EA-C34829E4C741

P407

Q35154029-3E49DF37-C366-45F0-B07B-8F43B256786C

P433

Q35154029-C0202C57-1FAE-491B-97EA-DE9D0B3700AF

P478

Q35154029-455EFFE2-8B53-429D-A014-0EAD1D70B80C

P577

Q35154029-71109F79-E10D-4910-9746-9CA620F2E244

P698

Q35154029-0663D42C-1AAC-4679-A5EB-96E721ABCAE3

P932

Q35154029-E864C4E1-1DFF-4CE7-8BB4-5887396EC779

P356

1078-0432.CCR-14-2550

P1433

Clinical Cancer Research

P1476

CCR 20th anniversary commentar ...... zomib in head and neck cancer.

@en

P2093

Barbara Conley

http://www.w3.org/2001/XMLSchema#string

Carter Van Waes

http://www.w3.org/2001/XMLSchema#string

Clint T Allen

http://www.w3.org/2001/XMLSchema#string

John B Sunwoo

http://www.w3.org/2001/XMLSchema#string

P2860

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Targeting NF-κB in mouse models of lung adenocarcinoma.

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

The immunoproteasome as a target in hematologic malignancies.

NF-κB and the link between inflammation and cancer.

Targeting the ubiquitin+proteasome system in solid tumors.

Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

P304

942-943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-2550

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25733706

http://www.w3.org/2001/XMLSchema#string

P932

4351792

http://www.w3.org/2001/XMLSchema#string